Akshay Vaishnaw
Equibles does not estimate personal net worth.
Get an email with a short summary when Alnylam Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALNY alertsAbout Akshay Vaishnaw
Scholar Rock Holding Corp reported in an 8-K filed April 28, 2025 that Akshay Vaishnaw was appointed President of Research & Development, effective April 27, 2025. The proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $3,317,190 for Akshay Vaishnaw in fiscal 2023, including a base salary of $647,800. Disclosed compensation is on record for 7 fiscal years. Alnylam Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Scholar Rock Holding Corp is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alnylam Pharmaceuticals, Inc. includes Yvonne Greenstreet (CEO and COO), Yvonne L. Greenstreet (CEO, COO and Board Member), Amy W. Schulman (Chairman and Board Member) and 7 others.
“The Board also appointed Akshay Vaishnaw, a current member of the Board, as the Company’s President of Research & Development (“R&D”), R. Keith Woods as the Company’s Chief Operating Officer and Vikas Sinha as the Company’s Chief Financial Officer, in each case effective on the Transition Date.”
Affiliation history
-
Alnylam Pharmaceuticals, Inc. (ALNY)
Proxy statement
CurrentStart not stated–present
Last confirmed April 1, 2024
-
Scholar Rock Holding Corp (SRRK)
Source not stated
Current -
2019-01-01–2024-04-29
Last confirmed by a filing; no departure on record
Company network
Leadership on record at Alnylam Pharmaceuticals, Inc.
- Yvonne Greenstreet CEO, COO
- Yvonne L. Greenstreet CEO, COO, Board Member
- Amy W. Schulman Chairman, Board Member
- Michael Bonney Chairman
- Michael W. Bonney Chairman
- Jeffrey Poulton CFO
- Manmeet S CFO
- Akshay K. Vaishnaw, M.D., Ph.D. CIO
- Benjamin F. Cravatt Board Member
- Benjamin F. Cravatt, Ph.D. Board Member
Leadership on record at Scholar Rock Holding Corp
- David Hallal CEO, Board Member
- Dr. Jay Backstrom CEO, Board Member
- Jay Backstrom, M.D., M.P.H. CEO, Board Member
- Nagesh K. Mahanthappa Ph.D CEO
- Erin Moore CFO, Chief Accounting Officer
- Rhonda M. Chicko CFO
- Vikas Sinha CFO
- R. Keith Woods COO
- Junlin Ho General Counsel, Board Member
- Caryn Parlavecchio Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. Former President | $647,800 | $3,317,190 |
| 2022 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. Former President | $725,000 | $3,591,620 |
| 2021 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. Former President | $632,200 | $5,425,035 |
| 2020 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. President | $634,600 | $2,892,226 |
| 2019 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. President,Research and Development | $586,530 | $3,100,952 |
| 2018 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. President,Research and Development | $570,000 | $2,619,671 |
| 2017 | Alnylam Pharmaceuticals, Inc. (ALNY) | M.D., Ph.D. President, Researchand Development | $542,141 | $915,218 |